Avelumab is a prescription medication that is used to treat adults and children 12 years of age and older with a certain type of cancer called metastatic Merkel cell carcinoma (MCC). It belongs to a class of drugs called immunomodulatory monoclonal antibodies. It works by boosting the body’s immune system to help fight the cancer cells. Avelumab is given as an intravenous (IV) infusion, usually every 2 weeks. It is available as a single-use vial in different strengths. Common side effects of avelumab include nausea, diarrhea, fatigue, fever, and infusion-related reactions.
Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication used for the treatment of certain types of cancers, including:
- Merkel cell carcinoma (MCC): A rare and aggressive form of skin cancer.
- Urothelial carcinoma (UC): A type of cancer that forms in the lining of the urinary tract, including the bladder, ureters, and kidneys.
- Renal cell carcinoma (RCC): A type of kidney cancer.
Avelumab is a type of immunotherapy, which is a treatment that helps the body's immune system fight cancer. It works by blocking a protein called PD-L1, which is found on some cancer cells and helps them to hide from the immune system. By blocking PD-L1, avelumab allows the immune system to recognize and attack the cancer cells.
Avelumab is given as an intravenous (IV) infusion, which means it is injected into a vein. The dosage and schedule of treatment will vary depending on the type of cancer being treated and the patient's individual condition.